KCM
REGN icon

Kingdon Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Kingdon Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-25,000
Closed -$8.73M – 129
2016
Q2 		$8.73M Buy
+25,000
New +$9.63M 0.48% 56

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Kingdon Capital Management's REGN Position: Q1 2020 in Review

Kingdon Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2020, closing a stake of 1,901 shares — an estimated $714K sold.

Kingdon Capital Management first reported a position in REGN in Q2 2019 and held it in 3 quarters. The position peaked at $17.3M in Q3 2019. 817 funds tracked by Wall St. Rank hold REGN as of Q1 2020.

  • Kingdon Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Kingdon Capital Management sold 1,901 Regeneron Pharmaceuticals shares in Q1 2020, an estimated $714K.
  • Kingdon Capital Management first reported a position in Regeneron Pharmaceuticals in Q2 2019 and held it in 3 quarters.
  • Kingdon Capital Management's Regeneron Pharmaceuticals position peaked at $17.3M in Q3 2019.
  • 817 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2020.

Based on Kingdon Capital Management's 13F filing for Q1 2020, filed 15 May 2020.